Puig-Pijoan, AlbertJimenez-Balado, JoanFernández-Lebrero, AidaGarcía-Escobar, GretaNavalpotro-Gómez, IreneContador, JoseManero Borràs, Rosa MaríaPuente Periz, Victor ManuelSuárez, AntoniMuñoz, Francisco J.Grau-Rivera, OriolSuárez-Calvet, MarcTorre Fornell, Rafael de laRoquer, JaumeOis Santiago, Angel Javier2023-10-112023-10-112024Puig-Pijoan A, Jimenez-Balado J, Fernández-Lebrero A, García-Escobar G, Navalpotro-Gómez I, Contador J, et al. Risk of cognitive decline progression is associated to increased blood-brain-barrier permeability: A longitudinal study in a memory unit clinical cohort. Alzheimers Dement. 2024 Jan;20(1):538-48. DOI: 10.1002/alz.134331552-5260http://hdl.handle.net/10230/58066Introduction: This study examined the relationship between blood-brain-barrier permeability (BBBp), measured by cerebrospinal fluid/serum albumin ratio (QAlb), and cognitive decline progression in a clinical cohort. Methods: This prospective observational study included 334 participants from the BIODEGMAR cohort. Cognitive decline progression was defined as an increase in Global Deterioration Scale and/or Clinical Dementia Rating scores. Associations between BBBp, demographics, and clinical factors were explored. Results: Male sex, diabetes mellitus, and cerebrovascular burden were associated with increased log-QAlb. Vascular cognitive impairment patients had the highest log-QAlb levels. Among the 273 participants with valid follow-up data, 154 (56.4%) showed cognitive decline progression. An 8% increase in the hazard of clinical worsening was observed for each 10% increase in log-QAlb. Discussion: These results suggest that increased BBBp in individuals with cognitive decline may contribute to clinical worsening, pointing to potential targeted therapies. QAlb could be a useful biomarker for identifying patients with a worse prognosis.application/pdfeng© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.info:eu-repo/semantics/articlehttp://dx.doi.org/10.1002/alz.13433Blood-brain barrierCerebrovascular diseaseCognitionDementiaVascular dementiainfo:eu-repo/semantics/openAccess